TABLE 5.
Associations between statin use and prostate cancer risk stratified by body mass index in a population-based case-control study, King County, Washington, 2002–2005
| Statin use | Cases (n = 779) |
Controls (n = 703) |
OR*† | 95% CI* | ||
| No. | % | No. | % | |||
| Body mass index <30 kg/m2 | ||||||
| None | 582 | 74.7 | 514 | 73.1 | 1.00 | |
| Ever use | 197 | 25.3 | 189 | 26.9 | 0.87 | 0.68, 1.11 |
| Current use | 187 | 24.0 | 176 | 25.0 | 0.89 | 0.69, 1.14 |
| Duration of use (years) | ||||||
| <5 | 108 | 13.9 | 101 | 14.4 | 0.91 | 0.67, 1.23 |
| ≥5 | 89 | 11.4 | 88 | 12.5 | 0.83 | 0.59, 1.15 |
| Continuous | 0.99 |
0.96, 1.02 |
||||
| Cases (n = 222) |
Controls (n = 239) |
OR† | 95% CI | |||
| No. |
% |
No. |
% |
|||
| Body mass index ≥30 kg/m2 | ||||||
| None | 130 | 58.6 | 163 | 68.2 | 1.00 | |
| Ever use | 92 | 41.4 | 76 | 31.8 | 1.45 | 0.99, 2.13 |
| Current use | 85 | 38.3 | 68 | 28.5 | 1.50 | 1.00, 2.24 |
| Duration of use (years) | ||||||
| <5 | 46 | 20.7 | 45 | 18.8 | 1.21 | 0.75, 1.96 |
| ≥5 | 46 | 20.7 | 31 | 13.0 | 1.80 | 1.06, 3.03 |
| Continuous | 1.05 | 1.00, 1.10 | ||||
*
OR, odds ratio; CI, confidence interval.
†
Adjusted for age, race, and prostate cancer screening within the 5-year period before the reference date.